SYNTHESIS OF CONGENERS AND PRODRUGS

NIH GUIDE, Volume 23, Number 4, January 28, 1994



RFP AVAILABLE:  NCI-CM-47012-20



P.T.





Keywords:



National Cancer Institute



The Drug Synthesis and Chemistry Branch (DS&CB) of the Developmental

Therapeutics Program (DTP), Division of Cancer Treatment (DCT),

National Cancer Institute (NCI) is seeking contractors with expertise

in chemical synthesis and drug design to synthesize a variety of

compounds for evaluation as potential anti-AIDS or anti-cancer

agents.  The assigned objectives of this project are to design and

synthesize the following: (a) congeners of lead compounds having

confirmed activity to enhance activity or potency; (b) prodrugs with

structural modifications that may provide altered pharmacokinetics,

altered drug transport, improved bio-availability through increased

water solubility, or increased chemical stability; (c) other altered

structures that possess elements of both congeners and prodrugs; and

(d) compounds related to natural products, e.g., alkaloids,

heterocycles, nucleosides, and peptides.



Each contractor should have available a fully operational facility,

including all necessary equipment and instrumentation for all aspects

of the contract.  The nature of this project requires that the

following restriction be applied: "The NCI signs legally binding

agreements with certain suppliers (often pharmaceutical or chemical

companies) that state that all information on compounds submitted by

the supplier will be held confidential.  The successful offeror will

be expected to synthetically modify such commercially confidential

(discreet) materials.  Thus, pharmaceutical or chemical companies

could obtain valuable data on new lead compounds.  Therefore, in

order to honor the confidentiality agreement with the original

supplier, the NCI believes that the compounds cannot be sent to

potential competitors of the supplier, and thus pharmaceutical and

chemical companies must be excluded from the competition."  For

purposes of this restriction, a pharmaceutical or chemical company is

defined as an organization that sells drugs and chemicals to the

general public for profit.  The Standard Industrial Classification

(SIC) number is 8731.  This is a recompetition of contracts currently

held by the Georgia Tech Research Corporation (Georgia Institute of

Technology), Purdue Research Foundation, and the University of

Tennessee.  It is anticipated that two cost-reimbursement contracts

will be awarded for a period of two years beginning on or about

September 30, 1994.



INQUIRIES



Request for Proposals (RFP) No. NCI-CM-47012-20 will be issued on or

about January 31, 1994 and proposals will be due approximately 30

days thereafter.  Copies of the RFP may be obtained by sending a

written request to:



Charles Lerner

Research Contracts Branch, TCS

National Cancer Institute

Executive Plaza South, Room 603

Bethesda, MD  20892

Telephone:  (301) 496-8603



.


Return to 1994 Index

Return to NIH Guide Main Index


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.